Expenses on Intangible Assets and Financial Performance of Listed Pharmaceuticals Companies in Bangladesh: An Empirical Investigation

The objective of the study is to examine the status of financial performance in relation with expenses on intangible assets (IA) of pharmaceuticals companies in Bangladesh. Data were collected from annual reports of the sample banks covering five years ranges 2019-2023. To analyse the data, statistical tools such as mean, standard deviation, Anova and regression, VIF, Durbin-watson statistics etc. were used. To reflect the financial performance, return on assets (ROA), return on equity (ROE) and earnings per share (EPS) are considered and it evident that Square Company is in the top in securing highest ROA, ROE and EPS and Silco Company is in the least in ROA and ROE. The ANOVA statistics tells that there is no significant variation in profitability in pharmaceuticals industry in Bangladesh year to year but there is statistically significant difference in profitability proxied by ROA, ROE and EPS among the sample companies during the study periods. It is seen that 66.67 % companies in pharmaceuticals companies in Bangladesh incur expenses on intangible assets. The regression results shows that there is no significant association between expenses on intangibles assets and profitability of sample banks during the study periods. This study provides supplemental data for standards setters, executives, and auditors regarding the significance of accounting system for intangible assets in the quality of financial reporting.